Longitudinal Anti-HBs Monitoring and Seroprotection Patterns in Rituximab-Treated Patients with Pemphigus Vulgaris: A Retrospective Cohort Study
Nur Ecer, Mehmet Harman · 2026
Read Longitudinal Anti-HBs Monitoring and Seroprotection Patterns in Rituximab-Treated Patients with Pemphigus Vulgaris: A Retrospective Cohort Study by Nur Ecer, Mehmet Harman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13605555.txt.
Description
Rituximab drains B cells for months, and with them can go the antibodies that guard against hepatitis B. The authors follow 84 patients with pemphigus vulgaris, an autoimmune blistering disease, treated with the drug between 2010 and 2026. All have antibody measurements before and after treatment. The team models the antibody trend over time and asks which patients fall below the standard protection threshold of 10 units per liter.
At the start, the median level is 49.7, yet 40.5 percent already sit below the threshold. Levels dip significantly at months 6, 9, and 18, though the chance of crossing below the threshold does not rise significantly overall. Patients carrying signs of past hepatitis B exposure keep far higher antibody levels. No case of viral reactivation is documented, though viral DNA was not routinely checked. The authors advise serological testing and care in reading serial antibody values in such patients.
Catalog record
| CREATOR | Nur Ecer, Mehmet Harman |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |